Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy NVS Stock  Free NVS Stock Alerts

Novartis (NVS) Financials

Novartis logo
$111.88 -1.33 (-1.17%)
Closing price 03:59 PM Eastern
Extended Trading
$111.48 -0.41 (-0.36%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Novartis

Annual Income Statements for Novartis

This table shows Novartis' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Income / (Loss) Attributable to Common Shareholders		 11,941 14,850 6,955 24,021 8,072 11,732 12,611 7,703 6,712
Consolidated Net Income / (Loss)		 11,939 14,854 6,955 24,018 8,071 11,737 12,614 7,703 6,698
Net Income / (Loss) Continuing Operations		 11,939 8,572 6,049 22,905 8,071 7,147 12,800 7,499 6,698
Total Pre-Tax Income 		13,640 9,123 7,177 24,530 9,878 8,940 14,095 9,102 7,817
Total Operating Income		 14,544 9,769 7,946 10,056 10,152 9,086 8,403 8,702 8,268
Total Gross Profit		 38,895 34,188 31,879 32,239 34,777 34,252 31,589 29,771 31,916
Total Revenue		 51,722 46,660 43,461 43,974 49,898 48,677 46,099 43,404 49,436
Operating Revenue		 50,317 45,440 42,206 42,781 48,659 47,498 44,833 42,381 48,518
Other Revenue		 1,405 1,220 1,255 1,193 1,239 1,179 1,266 1,023 918
Total Cost of Revenue		 12,827 12,472 11,582 11,735 15,121 14,425 14,510 13,633 17,520
Operating Cost of Revenue		 12,827 12,472 11,582 11,735 15,121 14,425 14,510 13,633 17,520
Total Operating Expenses		 24,351 24,419 23,933 22,183 24,625 25,166 23,186 21,069 23,648
Selling, General & Admin Expense		 12,566 12,517 12,193 12,827 14,197 14,369 13,717 12,465 14,192
Research & Development Expense		 10,022 11,371 9,172 8,641 8,980 9,402 8,489 8,389 9,039
Other Operating Expenses / (Income)		 2,938 2,303 3,264 2,335 1,448 3,426 980 2,137 417
Other Special Charges / (Income)		 -1,175 -1,772 -696 -1,620 - -2,031 - -1,922 -
Total Other Income / (Expense), net		 -904 -646 -769 14,474 -274 -146 5,692 400 -451
Interest Expense		 1,006 855 800 787 869 850 932 750 707
Other Income / (Expense), net		 102 209 31 15,261 595 704 6,624 1,150 256
Income Tax Expense		 1,701 551 1,128 1,625 1,807 1,793 1,295 1,603 1,119
Net Income / (Loss) Discontinued Operations		 0.00 6,282 906 1,113 - 4,590 -186 204 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 2.00 -4.00 0.00 3.00 1.00 -5.00 -3.00 0.00 14
Basic Earnings per Share		 $5.92 $7.15 $3.19 $10.71 $3.55 $5.12 $5.44 $3.28 $2.82
Weighted Average Basic Shares Outstanding		 1.98B 2.04B 2.12B 2.23B 2.26B 2.27B 2.34B 2.35B 2.38B
Diluted Earnings per Share		 $5.87 $7.10 $3.17 $10.63 $3.52 $5.06 $5.38 $3.25 $2.80
Weighted Average Diluted Shares Outstanding		 1.98B 2.04B 2.12B 2.23B 2.26B 2.27B 2.34B 2.35B 2.40B
Weighted Average Basic & Diluted Shares Outstanding		 1.98B 2.04B 2.12B 2.23B 2.26B 2.27B 2.34B 2.35B 2.38B

Quarterly Income Statements for Novartis

No quarterly income statements for Novartis are available.

Annual Cash Flow Statements for Novartis

This table details how cash moves in and out of Novartis' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Change in Cash & Equivalents		 -1,934 5,876 -4,890 2,749 -1,454 -2,159 4,411 1,853 2,333
Net Cash From Operating Activities		 17,619 14,458 14,236 15,071 5,584 13,625 14,272 12,621 11,475
Net Cash From Continuing Operating Activities		 17,619 14,220 13,039 13,365 5,584 13,547 13,049 11,419 11,475
Net Income / (Loss) Continuing Operations		 11,939 8,572 6,049 22,905 8,071 7,147 12,800 7,499 6,698
Consolidated Net Income / (Loss)		 11,939 8,572 6,049 22,905 8,071 7,147 12,800 7,499 6,698
Non-Cash Adjustments To Reconcile Net Income		 7,493 7,551 8,560 -8,692 -50 7,918 311 4,417 6,390
Changes in Operating Assets and Liabilities, net		 -1,813 -1,903 -1,570 -848 -2,437 -1,518 -62 -497 -1,613
Net Cash From Discontinued Operating Activities		 0.00 238 1,197 1,706 - 78 1,223 1,202 0.00
Net Cash From Investing Activities		 -7,513 5,596 1,468 4,208 -12,319 -2,226 -5,591 -3,119 -3,441
Net Cash From Continuing Investing Activities		 -7,513 6,719 1,904 4,897 -12,319 -1,067 -4,590 -2,344 -2,693
Purchase of Property, Plant & Equipment		 -3,814 -2,753 -2,239 -2,556 -1,275 -1,284 -2,648 -2,294 -2,879
Acquisitions		 -3,911 -3,558 -840 -205 -9,957 -3,760 -13,683 -714 -765
Purchase of Investments		 -3,648 -747 -34,811 -16,650 -1,900 -590 -2,684 -974 -926
Sale of Property, Plant & Equipment		 166 2,192 328 897 813 857 925 731 1,008
Divestitures		 -10 -11 -24 20,669 - -6.00 12,854 29 0.00
Sale and/or Maturity of Investments		 3,704 11,596 39,490 2,742 - 3,716 646 878 869
Net Cash From Discontinued Investing Activities		 0.00 -1,123 -436 -689 - -1,159 -1,001 -775 -748
Net Cash From Financing Activities		 -11,742 -14,278 -20,562 -16,264 -1,255 -13,627 -4,244 -7,733 -5,314
Net Cash From Continuing Financing Activities		 -11,742 -17,564 -20,681 -16,290 -1,255 -16,884 -4,077 -7,318 -5,314
Repurchase of Common Equity		 -8,331 -8,719 -10,652 -3,057 - -5,533 -2,036 -5,490 -1,109
Payment of Dividends		 -9,784 -9,478 -10,081 -9,530 - -9,840 -6,966 -6,683 -8,171
Issuance of Debt		 7,101 546 252 -3,547 - -1,489 4,543 4,289 3,751
Other Financing Activities, net		 -439 87 -200 -156 748 -22 748 566 215
Net Cash From Discontinued Financing Activities		 0.00 3,286 119 26 - 3,257 -167 -415 -
Effect of Exchange Rate Changes		 -298 100 -32 -266 - 69 -26 84 -387

Quarterly Cash Flow Statements for Novartis

No quarterly cash flow statements for Novartis are available.

Annual Balance Sheets for Novartis

This table presents Novartis' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Total Assets		 102,246 99,945 117,453 131,795 127,778 118,370 145,563 133,079
Total Current Assets		 29,704 30,481 36,910 45,718 29,673 29,504 35,563 28,208
Cash & Equivalents		 11,459 13,393 7,517 12,407 9,658 11,112 13,271 8,860
Accounts Receivable		 7,423 7,107 8,066 8,005 8,217 8,301 8,727 8,600
Inventories, net		 5,723 5,913 7,175 6,666 7,131 6,823 7,763 6,867
Current Deferred & Refundable Income Taxes		 133 426 268 278 239 254 248 202
Other Current Assets		 2,968 2,607 2,471 2,440 2,523 2,680 2,861 3,054
Other Current Nonoperating Assets		 1,998 1,035 11,413 15,922 1,905 334 2,693 625
Plant, Property, & Equipment, net		 9,458 9,514 10,764 11,545 12,263 12,069 15,696 16,464
Plant, Property & Equipment, gross		 9,458 9,514 10,764 11,545 12,263 12,069 15,696 16,464
Total Noncurrent Assets		 63,084 59,950 69,779 74,532 85,842 76,797 94,304 88,407
Long-Term Investments		 2,134 2,812 2,554 205 9,632 8,644 10,697 15,370
Goodwill		 24,756 23,341 29,301 29,595 29,999 26,524 35,294 31,750
Intangible Assets		 26,915 26,879 31,644 34,182 36,809 28,787 38,719 29,997
Noncurrent Deferred & Refundable Income Taxes		 4,359 4,309 3,739 3,743 3,933 7,909 8,699 8,229
Other Noncurrent Operating Assets		 4,920 2,609 2,541 6,807 5,469 4,933 895 3,061
Total Liabilities & Shareholders' Equity		 102,246 99,945 117,453 131,795 127,778 118,370 145,563 133,079
Total Liabilities		 58,120 53,195 58,030 63,973 71,112 62,819 66,871 58,852
Total Current Liabilities		 28,692 26,390 28,656 30,208 33,059 28,264 29,607 23,403
Short-Term Debt		 8,232 6,175 5,931 - - - 9,678 -
Accounts Payable		 4,572 4,926 5,146 5,553 5,403 5,424 5,556 5,169
Current Deferred & Payable Income Tax Liabilities		 1,599 1,893 2,533 2,415 2,458 2,194 2,038 1,723
Other Current Liabilities		 14,289 13,396 15,046 22,240 25,198 20,646 12,284 16,511
Total Noncurrent Liabilities		 29,428 26,805 29,374 33,765 38,053 34,555 37,264 35,449
Long-Term Debt		 21,366 18,436 20,244 - - - 22,470 -
Capital Lease Obligations		 1,568 1,598 1,538 1,621 1,719 1,703 0.00 -
Noncurrent Deferred & Payable Income Tax Liabilities		 2,419 2,248 2,686 3,070 3,141 5,867 7,475 5,168
Other Noncurrent Operating Liabilities		 4,075 4,523 4,906 29,074 33,193 26,985 7,319 30,281
Total Equity & Noncontrolling Interests		 44,126 46,750 59,423 67,822 56,666 55,551 78,692 74,168
Total Preferred & Common Equity		 44,046 46,667 59,342 67,655 56,598 55,474 78,614 74,227
Total Common Equity		 44,046 46,667 59,342 67,655 56,598 55,474 78,614 74,168
Common Stock		 793 825 890 901 913 936 944 969
Treasury Stock		 -53 -41 -92 -48 -53 -80 -69 -100
Other Equity Adjustments		 43,306 45,883 58,544 66,802 55,738 54,618 77,739 73,299
Noncontrolling Interest		 80 83 81 167 68 77 78 59

Quarterly Balance Sheets for Novartis

This table presents Novartis' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q4 2023 Q4 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 102,246 99,945 117,453
Total Current Assets		 29,704 30,481 36,910
Cash & Equivalents		 11,459 13,393 7,517
Accounts Receivable		 7,423 7,107 8,066
Inventories, net		 5,723 5,913 7,175
Current Deferred & Refundable Income Taxes		 133 426 268
Other Current Assets		 2,968 2,607 2,471
Other Current Nonoperating Assets		 1,998 1,035 11,413
Plant, Property, & Equipment, net		 9,458 9,514 10,764
Plant, Property & Equipment, gross		 9,458 9,514 10,764
Total Noncurrent Assets		 63,084 59,950 69,779
Long-Term Investments		 2,134 2,812 2,554
Goodwill		 24,756 23,341 29,301
Intangible Assets		 26,915 26,879 31,644
Noncurrent Deferred & Refundable Income Taxes		 4,359 4,309 3,739
Other Noncurrent Operating Assets		 4,920 2,609 2,541
Total Liabilities & Shareholders' Equity		 102,246 99,945 117,453
Total Liabilities		 58,120 53,195 58,030
Total Current Liabilities		 28,692 26,390 28,656
Short-Term Debt		 8,232 6,175 5,931
Accounts Payable		 4,572 4,926 5,146
Current Deferred & Payable Income Tax Liabilities		 1,599 1,893 2,533
Other Current Liabilities		 14,289 13,396 15,046
Total Noncurrent Liabilities		 29,428 26,805 29,374
Long-Term Debt		 21,366 18,436 20,244
Capital Lease Obligations		 1,568 1,598 1,538
Noncurrent Deferred & Payable Income Tax Liabilities		 2,419 2,248 2,686
Other Noncurrent Operating Liabilities		 4,075 4,523 4,906
Total Equity & Noncontrolling Interests		 44,126 46,750 59,423
Total Preferred & Common Equity		 44,046 46,667 59,342
Total Common Equity		 44,046 46,667 59,342
Common Stock		 793 825 890
Treasury Stock		 -53 -41 -92
Other Equity Adjustments		 43,306 45,883 58,544
Noncontrolling Interest		 80 83 81

Annual Metrics And Ratios for Novartis

This table displays calculated financial ratios and metrics derived from Novartis' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 10.85% 7.36% -1.17% -11.87% 2.51% 5.59% 6.21% -12.20% 0.00%
EBITDA Growth		 46.78% 25.08% -68.49% 135.57% 9.78% -34.85% 52.53% 15.58% 0.00%
EBIT Growth		 46.78% 25.08% -68.49% 135.57% 9.78% -34.85% 52.53% 15.58% 0.00%
NOPAT Growth		 38.69% 37.06% -28.68% 13.20% 14.20% -4.81% 6.44% 1.20% 0.00%
Net Income Growth		 -19.62% 113.57% -71.04% 197.58% -31.23% -6.95% 63.75% 15.00% 0.00%
EPS Growth		 -17.32% 123.97% -70.18% 201.99% -30.43% -5.95% 63.75% 15.00% 0.00%
Operating Cash Flow Growth		 21.86% 1.56% -5.54% 169.90% -59.02% -4.53% 13.08% 9.99% 0.00%
Free Cash Flow Firm Growth		 -54.23% 205.91% -418.22% -31.42% -66.22% 831.71% 106.22% 0.00% 0.00%
Invested Capital Growth		 7.15% -15.13% 60.48% 10.00% 0.07% -31.65% 10.14% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 75.20% 73.27% 73.35% 73.31% 69.70% 70.37% 68.52% 68.59% 64.56%
EBITDA Margin		 28.32% 21.38% 18.35% 57.57% 21.54% 20.11% 32.60% 22.70% 17.24%
Operating Margin		 28.12% 20.94% 18.28% 22.87% 20.35% 18.67% 18.23% 20.05% 16.72%
EBIT Margin		 28.32% 21.38% 18.35% 57.57% 21.54% 20.11% 32.60% 22.70% 17.24%
Profit (Net Income) Margin		 23.08% 31.83% 16.00% 54.62% 16.18% 24.11% 27.36% 17.75% 13.55%
Tax Burden Percent		 87.53% 162.82% 96.91% 97.91% 81.71% 131.29% 89.49% 84.63% 85.69%
Interest Burden Percent		 93.13% 91.43% 89.97% 96.89% 91.91% 91.32% 93.80% 92.39% 91.71%
Effective Tax Rate		 12.47% 6.04% 15.72% 6.62% 18.29% 20.06% 9.19% 17.61% 14.32%
Return on Invested Capital (ROIC)		 22.06% 15.13% 12.57% 24.05% 22.31% 15.87% 14.71% 29.04% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 15.61% 89.81% 10.08% -39.02% 23.49% -5.12% -5.61% 24.74% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 4.22% 12.86% -1.64% 14.54% -7.93% 1.63% 1.80% -8.27% 0.00%
Return on Equity (ROE)		 26.28% 27.98% 10.93% 38.59% 14.38% 17.50% 16.51% 20.77% 0.00%
Cash Return on Invested Capital (CROIC)		 15.16% 31.49% -33.87% 14.52% 22.24% 53.48% 5.06% -170.96% 0.00%
Operating Return on Assets (OROA)		 14.49% 9.18% 6.40% 19.51% 8.73% 7.42% 10.79% 7.40% 0.00%
Return on Assets (ROA)		 11.81% 13.67% 5.58% 18.51% 6.56% 8.89% 9.05% 5.79% 0.00%
Return on Common Equity (ROCE)		 26.23% 27.94% 10.91% 38.51% 14.37% 17.49% 16.51% 20.77% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 27.11% 31.83% 11.72% 35.50% 14.26% 21.16% 16.03% 10.38% 0.00%
Net Operating Profit after Tax (NOPAT)		 12,730 9,179 6,697 9,390 8,295 7,264 7,631 7,169 7,084
NOPAT Margin		 24.61% 19.67% 15.41% 21.35% 16.62% 14.92% 16.55% 16.52% 14.33%
Net Nonoperating Expense Percent (NNEP)		 6.45% -74.68% 2.49% 63.07% -1.18% 20.99% 20.32% 4.30% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 16.91% 12.58% 7.69% - - - - - -
Cost of Revenue to Revenue		 24.80% 26.73% 26.65% 26.69% 30.30% 29.63% 31.48% 31.41% 35.44%
SG&A Expenses to Revenue		 24.30% 26.83% 28.06% 29.17% 28.45% 29.52% 29.76% 28.72% 28.71%
R&D to Revenue		 19.38% 24.37% 21.10% 19.65% 18.00% 19.32% 18.41% 19.33% 18.28%
Operating Expenses to Revenue		 47.08% 52.33% 55.07% 50.45% 49.35% 51.70% 50.30% 48.54% 47.84%
Earnings before Interest and Taxes (EBIT)		 14,646 9,978 7,977 25,317 10,747 9,790 15,027 9,852 8,524
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 14,646 9,978 7,977 25,317 10,747 9,790 15,027 9,852 8,524
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 4.52 4.42 3.15 2.59 3.23 3.70 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 45.10 0.00 1,259.09 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.85 4.42 4.30 3.98 3.66 4.22 0.00 0.00 0.00
Price to Earnings (P/E)		 16.66 13.88 26.90 7.28 22.62 17.49 0.00 0.00 0.00
Dividend Yield		 3.88% 3.60% 3.97% 4.13% 3.83% 0.00% 4.29% 4.20% 5.02%
Earnings Yield		 6.00% 7.20% 3.72% 13.73% 4.42% 5.72% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.63 3.88 3.12 4.01 4.44 5.04 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 4.19 4.63 4.71 3.73 3.31 3.85 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 14.79 21.67 25.68 6.48 15.36 19.13 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 14.79 21.67 25.68 6.48 15.36 19.13 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 17.01 23.56 30.58 17.47 19.90 25.78 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.29 14.96 14.39 10.89 29.56 13.74 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 24.75 11.31 0.00 28.93 19.96 7.65 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.71 0.56 0.47 0.02 0.03 0.03 0.00 0.00 0.00
Long-Term Debt to Equity		 0.52 0.43 0.37 0.02 0.03 0.03 0.00 0.00 0.00
Financial Leverage		 0.27 0.14 -0.16 -0.37 -0.34 -0.32 -0.32 -0.33 0.00
Leverage Ratio		 2.22 2.05 1.96 2.09 2.19 1.97 1.82 1.79 0.00
Compound Leverage Factor		 2.07 1.87 1.76 2.02 2.02 1.80 1.71 1.66 0.00
Debt to Total Capital		 41.39% 35.92% 31.80% 2.33% 2.94% 2.97% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 10.93% 8.46% 6.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 30.46% 27.46% 25.00% 2.33% 2.94% 2.97% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.11% 0.11% 0.09% 0.24% 0.12% 0.13% 0.10% 0.08% 0.00%
Common Equity to Total Capital		 58.50% 63.96% 68.10% 97.43% 96.94% 96.89% 100.00% 100.00% 0.00%
Debt to EBITDA		 2.13 2.63 3.47 0.06 0.16 0.17 0.00 0.00 0.00
Net Debt to EBITDA		 1.20 1.00 2.21 -0.43 -1.64 -1.84 0.00 0.00 0.00
Long-Term Debt to EBITDA		 1.57 2.01 2.73 0.06 0.16 0.17 0.00 0.00 0.00
Debt to NOPAT		 2.45 2.86 4.14 0.17 0.21 0.23 0.00 0.00 0.00
Net Debt to NOPAT		 1.38 1.09 2.63 -1.17 -2.12 -2.49 0.00 0.00 0.00
Long-Term Debt to NOPAT		 1.80 2.18 3.25 0.17 0.21 0.23 0.00 0.00 0.00
Altman Z-Score		 3.04 3.17 2.61 2.75 2.18 2.66 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.18% 0.15% 0.19% 0.19% 0.13% 0.06% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 1.04 1.16 1.29 1.51 0.90 1.04 1.20 1.21 0.00
Quick Ratio		 0.66 0.78 0.54 0.68 0.54 0.69 0.74 0.75 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8,748 19,112 -18,046 5,671 8,269 24,476 2,627 -42,203 0.00
Operating Cash Flow to CapEx		 482.98% 2,577.18% 744.95% 908.44% 1,208.66% 3,190.87% 828.32% 807.49% 613.31%
Free Cash Flow to Firm to Interest Expense		 8.70 22.35 -22.56 7.21 9.52 28.80 2.82 -56.27 0.00
Operating Cash Flow to Interest Expense		 17.51 16.91 17.80 19.15 6.43 16.03 15.31 16.83 16.23
Operating Cash Flow Less CapEx to Interest Expense		 13.89 16.25 15.41 17.04 5.89 15.53 13.46 14.74 13.58
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.51 0.43 0.35 0.34 0.41 0.37 0.33 0.33 0.00
Accounts Receivable Turnover		 7.12 6.15 5.41 5.42 6.04 5.72 5.32 5.05 0.00
Inventory Turnover		 2.20 1.91 1.67 1.70 2.17 1.98 1.98 1.99 0.00
Fixed Asset Turnover		 5.45 4.60 3.90 3.69 4.10 3.51 2.87 2.64 0.00
Accounts Payable Turnover		 2.70 2.48 2.17 2.14 2.79 2.63 2.71 2.64 0.00
Days Sales Outstanding (DSO)		 51.27 59.35 67.48 67.32 60.41 63.84 68.60 72.32 0.00
Days Inventory Outstanding (DIO)		 165.55 191.51 218.10 214.57 168.42 184.54 184.01 183.85 0.00
Days Payable Outstanding (DPO)		 135.14 147.38 168.59 170.39 130.67 138.92 134.89 138.39 0.00
Cash Conversion Cycle (CCC)		 81.69 103.48 116.99 111.51 98.15 109.46 117.71 117.78 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 59,701 55,719 65,652 40,909 37,190 37,164 54,376 49,372 0.00
Invested Capital Turnover		 0.90 0.77 0.82 1.13 1.34 1.06 0.89 1.76 0.00
Increase / (Decrease) in Invested Capital		 3,982 -9,933 24,743 3,719 26 -17,212 5,004 49,372 0.00
Enterprise Value (EV)		 216,558 216,228 204,812 164,078 165,077 187,256 0.00 0.00 0.00
Market Capitalization		 198,905 206,141 187,089 174,902 182,580 205,232 0.00 0.00 0.00
Book Value per Share		 $21.55 $22.02 $28.00 $29.98 $24.99 $24.00 $33.54 $31.61 $0.00
Tangible Book Value per Share		 ($3.73) ($1.68) ($0.76) $1.72 ($4.51) $0.07 $1.96 $5.29 $0.00
Total Capital		 75,292 72,959 87,136 69,443 58,385 57,254 78,614 74,168 0.00
Total Debt		 31,166 26,209 27,713 1,621 1,719 1,703 0.00 0.00 0.00
Total Long-Term Debt		 22,934 20,034 21,782 1,621 1,719 1,703 0.00 0.00 0.00
Net Debt		 17,573 10,004 17,642 -10,991 -17,571 -18,053 -21,623 -24,230 0.00
Capital Expenditures (CapEx)		 3,648 561 1,911 1,659 462 427 1,723 1,563 1,871
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2,215 -3,127 6,668 3,103 -13,044 -9,872 -7,315 -4,055 0.00
Debt-free Net Working Capital (DFNWC)		 9,244 10,266 14,185 15,510 -3,386 1,240 5,956 4,805 0.00
Net Working Capital (NWC)		 1,012 4,091 8,254 15,510 -3,386 1,240 5,956 4,805 0.00
Net Nonoperating Expense (NNE)		 791 -5,675 -258 -14,628 224 -4,473 -4,983 -534 386
Net Nonoperating Obligations (NNO)		 15,575 8,969 6,229 -26,913 -19,476 -18,387 -24,238 -24,796 0.00
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -4.28% -6.70% 15.34% 7.06% -26.14% -20.28% -15.87% -9.34% 0.00%
Debt-free Net Working Capital to Revenue		 17.87% 22.00% 32.64% 35.27% -6.79% 2.55% 12.92% 11.07% 0.00%
Net Working Capital to Revenue		 1.96% 8.77% 18.99% 35.27% -6.79% 2.55% 12.92% 11.07% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $5.92 $7.15 $0.00 $10.71 $3.55 $5.12 $4.78 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 1.98B 2.04B 0.00 2.23B 2.26B 2.27B 2.63B 0.00 0.00
Adjusted Diluted Earnings per Share		 $5.87 $7.10 $0.00 $10.63 $3.52 $5.06 $4.72 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 1.98B 2.04B 0.00 2.23B 2.26B 2.27B 2.67B 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.98B 2.04B 0.00 2.23B 2.26B 2.27B 2.64B 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 11,702 7,514 6,111 7,877 8,295 5,640 7,631 5,586 7,084
Normalized NOPAT Margin		 22.62% 16.10% 14.06% 17.91% 16.62% 11.59% 16.55% 12.87% 14.33%
Pre Tax Income Margin		 26.37% 19.55% 16.51% 55.78% 19.80% 18.37% 30.58% 20.97% 15.81%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 14.56 11.67 9.97 32.17 12.37 11.52 16.12 13.14 12.06
NOPAT to Interest Expense		 12.65 10.74 8.37 11.93 9.55 8.55 8.19 9.56 10.02
EBIT Less CapEx to Interest Expense		 10.93 11.01 7.58 30.06 11.84 11.02 14.27 11.05 9.41
NOPAT Less CapEx to Interest Expense		 9.03 10.08 5.98 9.82 9.01 8.04 6.34 7.48 7.37
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 81.95% 63.81% 144.95% 39.68% 0.00% 83.84% 55.22% 86.76% 121.99%
Augmented Payout Ratio		 151.73% 122.51% 298.10% 52.41% 0.00% 130.98% 71.37% 158.03% 138.55%

Quarterly Metrics And Ratios for Novartis

No quarterly metrics and ratios for Novartis are available.

Frequently Asked Questions About Novartis' Financials

When does Novartis's fiscal year end?

According to the most recent income statement we have on file, Novartis' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Novartis' net income changed over the last 8 years?

Novartis' net income appears to be on an upward trend, with a most recent value of $11.94 billion in 2024, rising from $6.70 billion in 2016. The previous period was $14.85 billion in 2023. See where experts think Novartis is headed by visiting Novartis' forecast page.

What is Novartis's operating income?
Novartis's total operating income in 2024 was $14.54 billion, based on the following breakdown:
  • Total Gross Profit: $38.90 billion
  • Total Operating Expenses: $24.35 billion
How has Novartis revenue changed over the last 8 years?

Over the last 8 years, Novartis' total revenue changed from $49.44 billion in 2016 to $51.72 billion in 2024, a change of 4.6%.

How much debt does Novartis have?

Novartis' total liabilities were at $58.12 billion at the end of 2024, a 9.3% increase from 2023, and a 1.2% decrease since 2017.

How much cash does Novartis have?

In the past 7 years, Novartis' cash and equivalents has ranged from $7.52 billion in 2022 to $13.39 billion in 2023, and is currently $11.46 billion as of their latest financial filing in 2024.

How has Novartis' book value per share changed over the last 8 years?

Over the last 8 years, Novartis' book value per share changed from 0.00 in 2016 to 21.55 in 2024, a change of 2,154.9%.


Related Companies

This page (NYSE:NVS) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...
Crypto 101 Media | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...
Brownstone Research | Sponsored